# DISC VERY& DEVELOPMENT US 2025

## 02 - 03 October 2025 | San Diego, CA

Uniting North American biopharma decision-makers to innovate at speed, equipping them with the critical intelligence & partners they require to make informed pipeline decisions in early-stage R&D

## Past Speakers Included



GRAHAM DEMPSEY, Quiver



ERIC MUNSON, **Purdue University** 



JULIE ZHU, **GSK** 



FIONA MACK, Bayer



JAMIE TSUNG, Alnylam



OLIVER KITTEN, **Affilogic** 



JOE FRANKLIN, Anagenex



AMITA DATTA-MANNAN, Eli Lillu



MATT CHU, Astellas



# Discovery & Development US 2025

Developing new drugs has always been complex, costly, and slow, and this challenge is only exacerbated as the industry moves towards more innovative drug formats. R&D leaders must balance the need to discover novel modalities with the need to develop new methods and strategies that will make the process as fast and efficient as possible.

This is at the core of **Discovery & Development US 2025.** Our goal is to provide you with a clear roadmap from target identification to clinical candidate, no matter the drug modality or disease area on which you are focusing. We do this by providing relevant scientific, technological and business insights that enable you to develop innovative therapeutics at speed, whilst critically maintaining safety & efficacy.

Discovery & Development brings together three conferences together under one roof: our Drug Discovery Summit, Formulation & Delivery Congress and Biologics Congress - uniting experts in both small molecule and biologic drug development to deliver first-in-class drugs at pace.

## Benefits to Attending

Best Practice Case Studies: Discovery & Development US brings together world-class speakers who are scientific experts from every stage of the R&D pipeline. No matter the disease area or drug modality you're focussing on, you can be confident that you'll leave with real-world technical insights

Meaningful Networking & Partnership Building: With our audience of biopharma leaders, it's the perfect place to find your next strategic partner. Whether you're looking for a research collaborator, CRO, CDMO or technology provider, take advantage of over 9 hours of dedicated networking time to make the business connections you need for success

Intimate Knowledge-Sharing: Alongside case study presentations, the agenda features a host of roundtables, panels and workshops – enabling you to deep dive into specific pain points, form meaningful connections and come away with actionable next steps

More Stakeholders than ever before: The 2025 event will be the biggest yet, bringing together over 1000 experts from across the industry. Alongside our established community of biopharma and academic leaders, expect to connect with regulators, start-ups, investors and government organisations

Start-Up Zone: Reflecting our mission to accelerate and elevate innovation within the industry, this year's event will include a Start-Up Zone – featuring emerging companies developing game-changing technologies and innovative drug candidates









Welcome

Attendees

Sponsors

Session Topic Areas

Confirmed Speakers

PLUS Pass

**Book Now** 

Linked in

Market @OGConferences

# Network and Knowledge-Share

Connect with 1000+ VPs, Directors & KOLs from the most influential pharma, biotech and research organisations. We bring together the whole R&D ecosystem, including experts in:

- Target Discovery
- Target Validation
- Molecular Biology
- Hit Finding
- Medicinal Chemistry
- Library Design

- Pharmacology In Vitro/ In Vivo
- Biomarker Development
- Antibody Engineering
- Automation & Robotics
- Al Drug Discovery
- Discovery Technologies
- Formulation Science
- Preformulation Studies
- Drug Delivery
- Bioanalysis
- Device Development
- Process Chemistry

- Process Engineering
- RNA Delivery
- Protein Engineering
- Next-Generation **Biologics**
- Nanomedicine
- Analytical Chemistry

With new tools & platforms always under development, formal & informal networking opportunities provide a productive environment to form business partnerships. Solutions on show include:

- Contract Development
- Characterization Tools
- Effective Excipients
- Raw Materials
- Analytical Services
- Solubility & Stability **Testing**
- Dosage Forms
- Delivery Devices
- Formulation Development
- Display Technologies
- Controlled Release
- GMP Manufacturing
- Screening Technologies
- Library Optimisation
- Assay Development
- Novel Models
- Imaging Tools
- CRISPR

- Engineering Platforms
- Antibody Generation
- AI/ML Platforms
- Data Analytics
- Discovery Technologies
- Cell Generation

#### **Attendee Profile**



33% - Director

25% - VP/Head

20% - Principal/Senior Scientist

12% - Scientist

10% - C - Suite

GEOGRAPHY

85% - USA

10% - Europe

5% - RoW



30% - Biotech

25% - Pharma

20% - Vendor

10% - Academia

9% - Investors, Incubators & Accelerators

6% - Government & Regulators

## Attended by these companies & many more:







camurus.





**CoNCERT** 













**REGENERON** 



**Book Now** 

**BROCHURE CONTENTS** 

Welcome

**Attendees** 

Sponsors

Session

**Topic Areas** 

Confirmed

Speakers

**PLUS Pass** 



# Drive Innovation & Accelerate Research

**Platinum Sponsor** 



**Gold Sponsors** 







Silver Sponsors







QUANTUM SI

**Bronze Sponsor** 



**Networking & Programme Sponsors** 









**BROCHURE CONTENTS** 

Welcome

**Attendees** 

**Sponsors** 

Session

Confirmed Speakers

**PLUS Pass** 

**Book Now** 

**Linked** in  DAY 1

DAY 2

# **Explore Curated & Insightful Content**

The 2025 programme will explore the newest methods, tools and strategies that will support scientists developing innovative therapeutics at speed. Expect 200+ speakers, panelists and moderators, who will highlight best practice in every stage of the early R&D pipeline, shine a light on novel targets making a splash and deep dive into disease areas with significant unmet need.

#### DRUG DISCOVERY SUMMIT **DISCOVERY & DEVELOPMENT STRATEGIES Translating Targets Into Therapies** Target Identification & Validation Medicinal & Computational Chemistry Validating novel biomarkers to improve success in early New approaches in Computer-aided drug design Technological advancements, including Al, for the drug development discovery of novel new targets Progressing 'intractable targets' from a medicinal Streamlining translation of basic scientific findings into Identification & validation of novel small molecules chemistry & DMPK perspective human applications Hit Identification & Screening DMPK, Pharmacology & Safety **Targeting Neuroscience** Advances in molecular target-based and phenotypic Predicting & Measuring PK/PD, including computational Overcoming the blood-brain barrier in CNS diseases screening models Validating novel targets: ASOs, gene therapies, RNA-based Affinity/binding assays for hit ID Novel models for ADME-Tox Research & Disease Modelling treatments

|       | BIOLOGICS SUMMIT   |  |   |  |  |
|-------|--|--|---|--|--|
| DAY 1 | Antibody Discovery & Engineering     Novel engineering strategies to enhance antibody functions     Advanced technologies for new antibody discovery                                     | <ul> <li>Next-Gen Biologic Targets</li> <li>Next generation multi-specifics</li> <li>Identifying &amp; validating new, difficult targets</li> </ul>            | <ul> <li>Engineering Conjugates</li> <li>Strategies to optimise the design of ADCs</li> <li>Validating novel ADC targets, including next generation conjugates</li> </ul> |  |  |
| DAY 2 | Tools & Technologies For Antibody Discovery & Selection  Addressing difficult targets with display technologies Generating antibody libraries: NGS, cloning B cells, synthetic libraries | Computational Tools & Al/ML-Guided Engineering  Computational and analytical tools for protein engineering Al/ML & deep learning tools in antibody engineering | <ul> <li>Translating ADCs to the Clinic</li> <li>Maximising the efficacy of ADCs</li> <li>Developing appropriate preclinical models</li> </ul>                            |  |  |

|       | FORMULATION & DELIVERY SUMMIT  |  |   |   |  |
|-------|--|--|---|---|--|
|       | FORMULATION  | DELIVERY   | ANALYSIS  | NEW MODALITIES  |  |
| DAY 1 | Small Molecule Formulation     Overcoming challenges in small molecule drug formulation     Formulation of novel drug modalities: PROTACs, Molecular Glues       | Large Molecule Delivery     Moving beyond injectable delivery of biologics     Overcoming oral delivery challenges   | Preformulation Studies  Technologies for preformulation studies in pharmaceutical product development  Bioanalytical methods improving drug product development       | <ul> <li>RNA Design &amp; Delivery</li> <li>Overcoming challenges in RNA delivery</li> <li>Advanced techniques for delivery beyond the liver</li> </ul> |  |
| DAY 2 | Large Molecule Formulation  Innovative formulation strategies for ADCs, cell & gene therapies and more  Overcoming challenges in large molecule drug formulation | <ul> <li>Small Molecule Drug Delivery</li> <li>Novel routes of administration for small molecules</li> <li>Patient-friendly delivery and dosage forms</li> </ul> | Process Chemistry & Pharmaceutical Materials Analysis Choosing the correct excipient for your drug Utilizing cutting-edge technologies for analysis & quality control | Peptide & Oligo Design & Delivery  Drug delivery through the BBB Innovative technologies, like needle-free injections, Al & microneedles                |  |

Confirmed Speakers

PLUS Pass

**Book Now** 

Linked in

X @OGConferences

# Past Speakers Include

#### **GRAHAM DEMPSEY**

Founder & CSO, Quiver Bioscience

#### **FIONA MACK**

VP & Head of Co. Lab Cambridge, Bayer

#### **HONG CHENG**

VP & Head of Research Strategy, Sanofi

#### **JOE FRANKLIN**

SVP & Head of Early Drug Discovery, Anagenex

#### **SHELLEY ALLEN**

VP & Head of Drug Discovery, Nimble Therapeutics

#### **MARTIN REDHEAD**

AVP, Exscientia

#### **PAUL SCOLA**

Senior Director - Chemistry, Bristol Myers Squibb

#### **IULIA FOX**

Director - Data & Analytics, Takeda

#### **GIOVANNI PIEDIMONTE**

Vice President for Research & Professor of Pediatrics, Biochemistry & Molecular Biology, Tulane University

#### **GVIDO CEBERS**

Global Head of Drug Safety & Evaluation, Takeda

#### **IOSEPH WU**

Director & Professor, Stanford Cardiovascular Institute & Co-Founder, Greenstone Biosciences

#### **AMITA DATTA-MANNAN**

AVP & Clinical Team leader, Eli Lilly

#### **OLIVIER KITTEN**

Founder & CEO, Affilogic

#### **NATALIE GRINSHTEIN**

Director - ADC Discovery, Pfizer

#### **ANDREW VENDEL**

Senior Director, Immunology, Eli Lilly

## NAZNEEN DEWJI

CEO, Cenna Biosciences

#### **DENISE STECKEL**

Head of Clinical Collaborations Development, Genentech

#### CAITLIN MATERSON

Director, Technical Development, Gilead Sciences

#### MICHAEL COCHRAN

Director Chemistry, Avidity Biosciences

#### JONATHAN SOLOMON

Director, Novartis

### MIKE SCHOPPERLE

CEO, CureMeta

#### **ERIC MUNSON**

Professor and Head, Purdue University

#### **JACQUES VAN DAM**

VP, Medical Affairs, Rani Therapeutics

#### **IAMIE TSUNG**

Director, Head of DP Formulation, Alnylam Pharmaceuticals

#### **DAVID LOYND**

Chief Executive Officer, EnduRx Pharmaceuticals

#### **IULIE ZHU**

Scientific Director, GSK

#### **JUSTIN COHEN**

Director, Pfizer

#### LYNN KIRKPATRICK

Chief Executive Officer, Ensysce Pharmaceuticals

#### **RACHEL GROPPO**

Director, Lead saRNA Team, Johnson & Johnson Innovative Medicines

#### **ESMAIEL JABBARI**

Professor, University of South Carolina

#### **THOMAS BRADSHAW**

Chief Executive Officer, Neuronasal





Welcome

Attendees

**Sponsors** 

Session Topic Areas

Confirmed Speakers

**PLUS Pass** 

**Book Now** 

**Linked in**X @OGConferences

# Oxford Global PLUS Pass

Your Gateway to a Year of Unparalleled Knowledge-Sharing, Curated Experiences, and Global Networking!



BROCHURE CONTENTS

<u>Welcome</u>

Attendees

Sponsors

Session Topic Areas

Confimred Speakers

PLUS Pass

Book Now

## Welcome to the future of life sciences engagement!

#### **Effortless On-Demand Presentations**

Immerse yourself in competitor case studies, groundbreaking market developments, and captivating high-level strategy discussions via our comprehensive library of on-demand presentations.

## **Beneficial Partnerships and Accelerated Learning**

Foster invaluable partnerships for your business and accelerate high-end learning through peer-to-peer interactions. Participate in regular science exchange sessions, engaging group discussions, and dynamic inperson and online events that drive professional growth.

## **Year-Round Exclusive Insights**

Unlock a world of exclusive insights throughout the year via our online platform. Enjoy unrestricted access to commentaries, interviews with Key Opinion Leaders (KOLs), industry reports, and curated market intelligence content, keeping you at the forefront of industry trends.

Featuring content & recordings from all Oxford Global brands:















Digital Pass **£459**+VAT **\$680** 

Register Now

To receive bespoke proposal for group packages contact us at pluspass@oxfordglobal.com